Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum

ORLANDO, Fla., May 14, 2018 (GLOBE NEWSWIRE) — Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 4^th Annual Immuno-Oncology: BD&L and Investment Forum on Friday, June 1 at 3:40PM CDT (the time may be subject to changes depending on the conference organizers) at the Waldorf Astoria Chicago Hotel in Chicago, Illinois. Hemispherx is a research and development company focused on unmet medical needs in immunology, with a special emphasis in immuno-oncology. It is also an emerging commercial development company, based upon commercial approvals of Alferon® in the United States and Argentina for refractory or recurring external genital warts and Argentina for patients who become refractory to or intolerant to recombinant alpha interferon, as well as regulatory approval of Ampligen® in Argentina for severe Chronic Fatigue Syndrome (CFS).